NASDAQ:CERS - Cerus Stock Price, Forecast & News

Cerus trades on the NASDAQ under the ticker symbol "CERS."

Cerus Co. (NASDAQ:CERS) announced its quarterly earnings results on Wednesday, October, 30th. The biotechnology company reported ($0.13) earnings per share for the quarter, missing analysts' consensus estimates of ($0.12) by $0.01. The biotechnology company had revenue of $18 million for the quarter, compared to analyst estimates of $17.69 million. Cerus had a negative net margin of 100.38% and a negative return on equity of 100.59%. Cerus's revenue was up 16.9% on a year-over-year basis. During the same quarter in the prior year, the business earned ($0.11) earnings per share. View Cerus' Earnings History.

Cerus is scheduled to release their next quarterly earnings announcement on Tuesday, February 25th 2020. View Earnings Estimates for Cerus.

Cerus issued an update on its FY 2019 IntraDay earnings guidance on Monday, January, 13th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $74.6-74.6 million, compared to the consensus revenue estimate of $92.01 million.

3 analysts have issued 12 month target prices for Cerus' shares. Their forecasts range from $7.00 to $8.00. On average, they anticipate Cerus' stock price to reach $7.33 in the next year. This suggests a possible upside of 63.3% from the stock's current price. View Analyst Price Targets for Cerus.

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cerus in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Cerus.

News articles about CERS stock have trended somewhat negative this week, according to InfoTrie Sentiment Analysis. The research group scores the sentiment of press coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Cerus earned a news sentiment score of -1.4 on InfoTrie's scale. They also assigned press coverage about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the company's share price in the near future. View News Stories for Cerus.

Cerus saw a increase in short interest in December. As of December 13th, there was short interest totalling 9,520,000 shares, an increase of 13.7% from the November 28th total of 8,370,000 shares. Based on an average daily volume of 931,600 shares, the short-interest ratio is presently 10.2 days. Approximately 7.0% of the company's shares are short sold. View Cerus' Current Options Chain.

Some companies that are related to Cerus include Align Technology (ALGN), Cooper Companies (COO), DENTSPLY SIRONA (XRAY), West Pharmaceutical Services (WST), Haemonetics (HAE), ICU Medical (ICUI), Neogen (NEOG), Quidel (QDEL), Merit Medical Systems (MMSI), STAAR Surgical (STAA), Atrion (ATRI), Antares Pharma (ATRS), Anika Therapeutics (ANIK), OraSure Technologies (OSUR) and Meridian Bioscience (VIVO).

Based on aggregate information from My MarketBeat watchlists, some companies that other Cerus investors own include Rite Aid (RAD), SCYNEXIS (SCYX), Alibaba Group (BABA), Immunomedics (IMMU), Inovio Pharmaceuticals (INO), Opko Health (OPK), Celldex Therapeutics (CLDX), Omeros (OMER), Grayscale Bitcoin Trust (Btc) (GBTC) and Aduro BioTech (ADRO).

Cerus' stock is owned by many different of retail and institutional investors. Top institutional investors include Peregrine Capital Management LLC (1.70%), First Midwest Bank Trust Division (0.05%), Janney Montgomery Scott LLC (0.05%), Alpine Global Management LLC (0.01%) and Exchange Traded Concepts LLC (0.01%). Company insiders that own Cerus stock include Carol Moore, Chrystal Menard, Gail Schulze, Kevin Dennis Green, Laurence M Corash, Richard J Benjamin, Timothy B Anderson and William Mariner Greenman. View Institutional Ownership Trends for Cerus.

CERS stock was sold by a variety of institutional investors in the last quarter, including First Midwest Bank Trust Division. Company insiders that have sold Cerus company stock in the last year include Carol Moore, Gail Schulze, Kevin Dennis Green, Richard J Benjamin, Timothy B Anderson and William Mariner Greenman. View Insider Buying and Selling for Cerus.

CERS stock was purchased by a variety of institutional investors in the last quarter, including Peregrine Capital Management LLC, Alpine Global Management LLC, Exchange Traded Concepts LLC and Janney Montgomery Scott LLC. Company insiders that have bought Cerus stock in the last two years include Laurence M Corash and William Mariner Greenman. View Insider Buying and Selling for Cerus.

Shares of CERS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of CERS stock can currently be purchased for approximately $4.49.

Cerus has a market capitalization of $630.04 million and generates $60.91 million in revenue each year. The biotechnology company earns $-57,560,000.00 in net income (profit) each year or ($0.44) on an earnings per share basis. Cerus employs 240 workers across the globe.View Additional Information About Cerus.

The official website for Cerus is http://www.cerus.com/.

Cerus' mailing address is 1220 CONCORD AVENUE SUITE 600, CONCORD CA, 94520. The biotechnology company can be reached via phone at 925-288-6000 or via email at [email protected]